Xanthine Oxidoreductase Is a Regulator of Adipogenesis and PPARγ Activity

This publication has 48 references indexed in Scilit:

• Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure
  Journal of Molecular and Cellular Cardiology, 2005
• Obesity, Weight Change, Hypertension, Diuretic Use, and Risk of Gout in Men
  Archives of internal medicine (1960), 2005
• Krox20 stimulates adipogenesis via C/EBPβ-dependent and -independent mechanisms
  Cell Metabolism, 2005
• Microarray Analysis Supports a Role for CCAAT/Enhancer-binding Protein-β in Brain Injury
  Journal of Biological Chemistry, 2004
• Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications
  The Journal of Physiology, 2004
• Uric acid: role in cardiovascular disease and effects of losartan
  Current Medical Research and Opinion, 2004
• Uric acid in cachectic and noncachectic patients with chronic heart failure: Relationship to leg vascular resistance
  American Heart Journal, 2001
• Multiple initiators and C/EBP binding sites are involved in transcription from the TATA-less rat XDH/XO basal promoter
  Nucleic Acids Research, 1995
• Diphenylene iodonium as an inhibitor of the NADPH oxidase complex of bovine neutrophils
  European Journal of Biochemistry, 1992
• Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.
  Genes & Development, 1991